NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: WINDLAS · data 2026-10-31
Windlas Biotech Ltd.
In plain words
Price: 25.9% below its 52-week high of ₹1,181.9.
Delivery: 51.6% of traded shares were kept for delivery over the last 10 sessions, against 47.6% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹942 cr |
| Net profit (last 12 months) | ₹66 cr |
| Sales growth, 3 years (yearly) | 20.8% |
| Profit growth, 3 years (yearly) | 16.0% |
At a glance
Promoters 63.3% (+1.3 pts in a year), pledged 0.0%, institutions 9.3%.
P/E 28.0, dividend yield 0.7%. Price relative to earnings and book value (low is cheaper, not better).
ROE 12.2%, ROCE 13.5%, operating margin 7.9%: how much profit it earns on the money it uses.
Debt/equity 0.06, Profit growth 16.0% and sales growth 20.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Profit grew 16.0% a year over 3 years.
- Promoters raised their holding by 1.3 points in a year.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
15/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 49.4% over the last 20 sessions vs 29.9% in the 40 before (1.65x); shares delivered per day 0.62x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend
- 16 Jul 26Dividend Dividend ₹6.3 (ex-date) +0.5% next session
- 21 Jul 25Dividend Dividend ₹5.8 (ex-date) -0.5% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 63.31% | 63.31% | 61.90% | 61.99% |
| Foreign institutions (FII) | 2.08% | 2.04% | 0.60% | 0.93% |
| Domestic institutions (DII) | 7.24% | 9.84% | 11.81% | 11.44% |
| Mutual funds | 3.10% | 5.76% | 7.08% | 6.63% |
| Retail investors | 20.04% | 18.97% | 19.48% | 19.73% |
| Number of shareholders | 48,732 | 44,996 | 44,769 | 45,461 |
Common questions
How much do promoters hold in Windlas Biotech Ltd.?
Promoters held 63.31% of Windlas Biotech Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Windlas Biotech Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.06, which is very low.
What is Windlas Biotech Ltd.'s P/E ratio?
About 28, based on the last 12 months' earnings and a price of ₹876.1 (data 2026-10-31).
What is the 52-week high and low of Windlas Biotech Ltd.?
The 52-week high is ₹1,181.9 and the 52-week low is ₹697.4.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Windlas Biotech Ltd. | ₹876.1 | ₹1,810 cr | 28 | — | 12.2% | 13.5% | 0.06 | -8.4% |
| Hester Biosciences Limited | ₹2,289.3 | ₹1,956 cr | 14.3 | — | 16.5% | 13% | 0.54 | +40.7% |
| Indoco Remedies Limited | ₹208.3 | ₹1,923 cr | 60.1 | 1.9 | -9.7% | -2% | 1.15 | -25.0% |
| Panacea Biotec Limited | ₹313.25 | ₹1,917 cr | — | — | -0.6% | -6.3% | 0.03 | -29.8% |
| Syncom Formulation (India) Ltd. | ₹19.24 | ₹1,810 cr | 21.2 | — | 20.2% | 16.3% | 0 | +16.0% |
| Venus Remedies Limited | ₹1,238.6 | ₹1,646 cr | 13.6 | 2.4 | 16.8% | 14.5% | 0.02 | +182.9% |
Compare WINDLAS with HESTERBIO in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open WINDLAS in NSE Scanner →